Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2012-04-21 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于举行2011年年度报告网上业绩说明会的通知
Report Publication Announcement Classification · 95% confidence The document is a notice about holding an online performance explanation meeting for the 2011 annual report. It mentions the annual report has already been published and is available on specified websites. The document is short (585 characters) and serves as an announcement inviting investors to participate in the meeting rather than containing the report itself or detailed financial data. Therefore, it fits the category of Report Publication Announcement (RPA).
2012-04-21 Chinese
2011年日常关联交易执行情况及2012年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the execution of related party transactions in 2011 and the expected related party transactions for 2012. It includes detailed tables of transaction amounts, descriptions of related parties, pricing policies, and board approval information. The document references compliance with Shenzhen Stock Exchange listing rules and includes independent directors' opinions. It is not a full financial report but a regulatory announcement about related party transactions, which is a common disclosure under regulatory filings. The document length is 3579 characters, relatively short, and it does not contain comprehensive financial statements or management discussion typical of annual or interim reports. It is not a report publication announcement since it contains substantive disclosure content. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2012-04-21 Chinese
监事会对公司2011年内部控制自我评价报告的意见
Regulatory Filings Classification · 95% confidence The document is an opinion statement from the Supervisory Board regarding the company's 2011 internal control self-evaluation report. It references regulatory guidelines and confirms the effectiveness of internal controls but does not contain the full internal control report itself. The document is short (526 characters) and serves as an attestation or certification of the internal control report rather than the report itself. According to the Certification Rule and the Menu vs Meal Rule, this type of document should be classified as a Regulatory Filing (RNS) rather than the full Annual Report or Audit Report.
2012-04-21 Chinese
2011年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2011 年度财务决算报告' which translates to '2011 Annual Financial Settlement Report'. It contains detailed financial data including total assets, liabilities, net assets, revenue, profit, cash flow, and comparative figures for 2010 and 2011. The document also includes analysis and explanations of financial results and operational performance for the full fiscal year 2011. The presence of comprehensive financial statements and management analysis for a full fiscal year indicates this is an Annual Report. The document length is 2241 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it should be classified as an Annual Report (10-K). FY 2011
2012-04-21 Chinese
2012年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2012 First Quarter Quarterly Report" of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary on financial performance for the first quarter of 2012. The report explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. The audit report section notes that the financials are unaudited, which is typical for interim/quarterly reports. There is no indication that this is an announcement or a summary; the document contains substantive financial data and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2012
2012-04-21 Chinese
2011年度证券投资专项说明
Regulatory Filings Classification · 95% confidence The document is titled '2011年度证券投资专项说明' which translates to '2011 Annual Special Explanation on Securities Investment'. It details the company's securities investment activities during the 2011 fiscal year, including investment amounts, losses, and compliance with internal controls. The document includes tables of securities held, investment amounts, and losses, as well as an independent director's opinion on the securities investment activities. The content is focused on a specific aspect of the company's financial activities (securities investment) rather than a full annual report or quarterly report. It is not a general annual report (10-K), nor an earnings release or management discussion. It is a specialized report on securities investment activities, which is not a standard category but fits best under Regulatory Filings (RNS) as it is a compliance and disclosure document related to securities investment and internal controls. The document length is 2573 characters, which is relatively short and detailed, not just an announcement of a report. Therefore, the best classification is Regulatory Filings (RNS).
2012-04-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.